title: [Predictors of clinically significant bleeding events in bivalirudin-treated Chinese patients with acute myocardial infarction undergoing percutaneous coronary intervention].
abstract: Objective:This study was designed to further clarify the independent predictors of clinically significant bleeding events in bivalirudin-treated patients with acute myocardial infarction(AMI) undergoing percutaneous coronary intervention (PCI).Methods:A total of 3 023 AMI patients from 88 centers of China who underwent PCI and received periprocedural bivalirudin treatment between August 2012 and December 2015 were involved in this study.The primary outcome was clinically significant bleeding events defined as the Bleeding Academic Research Consortium(BARC) grades 2-5, with 30 days after PCI.A multivariate Logistic regression model was performed to identify the independent predictors of the primary outcome.Results:Bleeding events occurred in 88(2.9%) patients during the 30-day follow up, with clinically significant bleeding (BARC types 2-5) in 22(0.7%) and BARC types 3-5 in 7(0.2%). Multivariate regression analysis revealed radial access (OR: 0.196, 95%CI: 0.074-0.517,P=0.001) as the independent protector of the significant bleeding events, anemia (OR: 2.956, 95%CI: 1.024-8.528,P=0.045) and eGFR<30 ml/min (OR: 7.860, 95%CI: 1.515- 40.776,P=0.014) as independent risk factors.Conclusions:The rate of clinically significant bleeding complications in Chinese AMI patients undergoing PCI with concomitant use of bivalirudin is low in real-world clinical practice.Radial access is independent protective factor that reduces bleeding events, whereas anemia and eGFR <30 ml/min are independent risk factors that increase bleeding risk.
authors.affiliation: Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110016, China.
authors.forename: H Y
authors.initials: HY
authors.lastname: Wang
authors.forename: Y L
authors.initials: YL
authors.lastname: Han
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Liang
authors.forename: J
authors.initials: J
authors.lastname: Qian
authors.forename: Z
authors.initials: Z
authors.lastname: Ji
authors.forename: L Q
authors.initials: LQ
authors.lastname: Cui
authors.forename: H P
authors.initials: HP
authors.lastname: Xu
mesh_terms: D000991:Antithrombins; D002681:China; D006470:Hemorrhage; D006493:Heparin; D006629:Hirudins; D006801:Humans; D016015:Logistic Models; D009203:Myocardial Infarction; D010446:Peptide Fragments; D062645:Percutaneous Coronary Intervention; D011994:Recombinant Proteins; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin
keywords: Angioplasty; Anticoagulants; Bleeding; Myocardial Infarction